急性髓系白血病患者异基因造血干细胞移植后的心脏事件
这项由GETH-TC资助的多中心研究纳入1020例接受蒽环类治疗的急性髓系白血病患者,分析异基因造血干细胞移植后早期(前100天)和晚期心脏事件的发生率与预测因素,并探讨移植后环磷酰胺(PTCY)对心脏并发症及总生存(OS)和非复发死亡(NRM)的影响。
要点
- 1020例患者中94例(9.2%)发生心脏事件,心律失常、心包并发症和心力衰竭最常见。
- 早期心脏事件49例(4.8%),移植后中位13天发生;晚期心脏事件45例(4.4%),移植后中位3.6年发生。
- 多因素分析显示PTCY增加早期心脏事件风险(HR 2.86,P=0.007),但不显著影响晚期心脏事件风险(HR 1.06,P=0.892)。
核心结论
- 心脏事件发生率相对较低,但显著影响死亡率。
- 标准剂量PTCY增加早期心脏事件风险,但与总生存改善相关。
- 需要制定预防这些患者心脏并发症的方案。
研究设计与样本
- 由GETH-TC资助的多中心研究,纳入1020例接受蒽环类治疗的急性髓系白血病患者。
- 450例(44.1%)成人接受PTCY。
- 分析异基因造血干细胞移植后早期(前100天)和晚期心脏事件的发生率与预测因素。
主要发现
- 94例(9.2%)患者发生心脏事件,心律失常、心包并发症和心力衰竭最常见。
- 早期心脏事件49例(4.8%),移植后中位13天发生;晚期心脏事件45例(4.4%),移植后中位3.6年发生。
- 多因素分析中PTCY增加早期心脏事件风险(HR 2.86,P=0.007),但不显著影响晚期心脏事件风险(HR 1.06,P=0.892)。
- 心脏事件诊断降低总生存可能性(HR 1.66,P=0.005),增加非复发死亡可能性(HR 2.88,P<0.001)。
- PTCY虽增加早期心脏事件风险,但对总生存有益(HR 0.71,P=0.026)。
临床怎么用
- 原文结论指出需要制定预防这些患者心脏并发症的方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This multicenter study sponsored by the GETH-TC investigates the incidence and predictors of early (first 100 days) and late cardiac events (CEs; ECEs and LCEs, respectively) after allo-HCT in patients with acute myeloid leukemia (AML) treated with anthracyclines, focusing on exploring the impact of PTCY on cardiac complications and the impact of CEs on OS and NRM. A total of 1020 patients with AML were included. PTCY was given to 450 (44.1%) adults. Overall, 94 (9.2) patients experienced CEs, with arrythmias, pericardial complications, and heart failure the most prevalent. ECEs occurred in 49 (4.8%) patients within a median of 13 days after allo-HCT, whereas LCEs were diagnosed in 45 (4.4%) patients within a median of 3.6 years after transplant. Using PTCY increased the risk for ECEs in multivariate analysis (hazard ratio [HR], 2.86; P = .007) but did not significantly affect the risk for LCEs (HR, 1.06; P = .892). The impact of variables on outcomes revealed was investigated using multivariate regression analyses and revealed that the diagnosis of CEs decreased the likelihood of OS (HR, 1.66; P = .005) and increased the likelihood of NRM (HR, 2.88; P < .001). Furthermore, despite using PTCY increased ECEs risk, its administration was beneficial for OS (HR, 0.71; P = .026). In conclusion, although the incidence of CEs was relatively low, it significantly affected mortality. Standard doses of PTCY increased ECE risk but were associated with improved OS. Therefore, protocols for preventing cardiac complications among these patients are needed.
引用
- Salas MQ, Cascos E, López-García A, et al. Cardiac events after allo-HCT in patients with acute myeloid leukemia. Blood Adv. 2024. PMID: 39178345. doi:10.1182/bloodadvances.2024013535
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。